Lead Product(s): Fluticasone Propionate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance
Highest Development Status: Approved Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, rapidly increasing promotional reach and frequency.